...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.
【24h】

Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.

机译：肝素给药后组织因子减少和组织因子途径抑制剂释放。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Elevated plasma levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) and large amounts of monocyte procoagulant activity (PCA) have been documented in unstable angina (UA) patients. In in vitro experiments heparin is able to blunt monocyte TF production by inhibiting TF and cytokine gene expression by stimulated cells and after in vivo administration it reduces adverse ischemic outcomes in UA patients. TF and TFPI plasma levels and monocyte PCA have been investigated in 28 refractory UA patients before and during anticoagulant subcutaneous heparin administration (thrice daily weight- and PTT-adjusted for 3 days) followed by 5000 IU X 3 for 5 days. After 2-day treatment, immediately prior to the heparin injection, TF and TFPI plasma levels [(median and range): 239 pg/ml, 130-385 pg/ ml and 120 ng/ml, 80-287 ng/ml] were lower in comparison to baseline samples (254.5 pg/ml, 134.6-380 pg/ml and 135.5 ng/ml, 74-306 ng/ml). Four h after the heparin injection TF furtherly decreased (176.5 pg/ml, 87.5-321 pg/ml; -32.5%. p<0.001) and TFPI increased (240.5 ng/ml, 140-450 ng/ml; +67%, p<0.0001). After 7-day treatment, before the injection of heparin, TF and TFPI plasma levels (200 pg/ml, 128-325 pg/ml and 115 ng/ml, 70-252 ng/ml) significantly decreased (p<0.05) in comparison to the pre-treatment values. On the morning of the 8th day, 4 h after the injection of heparin TF plasma levels and monocytes PCA significantly decreased (156.5 pg/ml, 74-259 pg/ml and from 180 U/105 monocytes, 109-582 U/10(5) monocytes to 86.1 U/10(5) monocytes, 28-320 U/10(5) monocytes; - 38% and -55% respectively) and TFPI increased (235.6 ng/ml, 152-423 ng/ ml; +70%, p<0.001). In conclusion, heparin treatment is associated with a decrease of high TF plasma levels and monocyte procoagulant activity in UA patients. These actions of heparin may play a role in determining the antithrombotic and antiinflammatory properties of this drug.
机译：不稳定型心绞痛（UA）患者的血浆血浆组织因子（TF）和组织因子途径抑制剂（TFPI）水平升高以及大量单核细胞促凝活性（PCA）已被记录。在体外实验中，肝素能够通过抑制刺激细胞的TF和细胞因子基因表达来抑制单核细胞TF的产生，并且在体内给药后，它可以减少UA患者的不良缺血结果。在抗凝剂皮下给予肝素之前和期间（28次每日体重和PTT调整3天），然后在5000 IU X 3下连续5天，对28例难治性UA患者进行了TF和TFPI血浆水平以及单核细胞PCA的研究。治疗2天后，即刻在肝素注射之前，TF和TFPI血浆水平[（中位数和范围）：239 pg / ml，130-385 pg / ml和120 ng / ml，80-287 ng / ml]与基线样品相比更低（254.5 pg / ml，134.6-380 pg / ml和135.5 ng / ml，74-306 ng / ml）。肝素注射后四小时TF进一步降低（176.5 pg / ml，87.5-321 pg / ml; -32.5％。p <0.001），TFPI增加（240.5 ng / ml，140-450 ng / ml; + 67％， p <0.0001）。治疗7天后，在肝素注射前，血浆中的TF和TFPI血浆水平（200 pg / ml，128-325 pg / ml和115 ng / ml，70-252 ng / ml）显着降低（p <0.05）与预处理值的比较。在第8天的早晨，注射肝素TF后血浆血浆水平和单核细胞PCA显着降低（156.5 pg / ml，74-259 pg / ml和180 U / 105单核细胞，109-582 U / 10（ 5）单核细胞增至86.1 U / 10（5）单核细胞，28-320 U / 10（5）单核细胞;分别为38％和-55％）和TFPI增加（235.6 ng / ml，152-423 ng / ml; + 70％，p <0.001）。总之，在UA患者中，肝素治疗与高TF血浆水平和单核细胞促凝活性的降低有关。肝素的这些作用可能在确定该药物的抗血栓形成和抗炎特性中起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号